Astellas(US:ALPMY)2024-08-01 11:45Financial Performance - Revenue increased by 262% YoY, reaching 4731 billion yen, with a foreign exchange impact of +454 billion yen[4] - Core operating profit increased by 205% YoY to 883 billion yen, with a foreign exchange impact of +116 billion yen[4] - Strategic Brands expanded to 750 billion yen, representing a threefold increase YoY of approximately +500 billion yen[4, 5] Key Products - XTANDI contributed significantly to overall revenue growth, particularly in the US, with sales of 2242 billion yen, a 29% increase YoY (+502 billion yen)[4, 5] - PADCEV global sales reached 384 billion yen, a 152% increase YoY (+232 billion yen)[6] US sales were $174 million (+128%), and EST sales were €45 million (+178%)[7] - IZERVAY US sales were $82 million, with a market share of approximately 35% in Q1/FY2024, representing a QoQ growth of +73%[10, 11] - VEOZAH global sales were 66 billion yen, a 972% increase YoY (+60 billion yen)[6] US sales were $39 million (+778%), and EST sales were €3 million (+3)[9] Cost Items - SG&A expenses increased by 230% YoY to 2069 billion yen, with a foreign exchange impact of +208 billion yen[4] Excluding US XTANDI co-pro fee, SG&A expenses increased by 175% YoY (+217 billion yen)[4] - R&D expenses increased by 344% YoY to 868 billion yen, with a foreign exchange impact of +69 billion yen[4] Pipeline and Strategy - The company is pursuing product value maximization for ZOLBETUXIMAB / VYLOY as a first-in-class anti-CLDN182 treatment, with a regulatory decision anticipated for Q4/FY2024[15] - A new Phase 3 study for ZOLBETUXIMAB / VYLOY in combination with CPI and chemotherapy is planned to start in 1H/CY2025[15] - The company is investing in business growth, aiming for higher dividend increases aligned with robust profit growth forecasts[27]